ONO PHARMACEUTICAL CO., LTD.

Harness Therapeutics has launched MISBA Duo, the first platform enabling simultaneous upregulation and downregulation of two targets for neurodegenerative disease treatment.

• Fate Therapeutics' FT825/ONO-8250, a HER2-targeting CAR-T cell therapy, shows a favorable safety profile in an early-stage trial for advanced solid tumors. • Preclinical data highlights the therapy's cancer-selective HER2 targeting, reducing off-tumor toxicities compared to traditional HER2-directed treatments. • Initial results from the Phase 1 study indicate CAR T-cell expansion and activation in patients, suggesting potential for clinical efficacy. • The FT825 / ONO-8250 incorporates seven novel synthetic controls of CAR T-cell function designed to overcome multiple mechanisms.